Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.
Title | Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab. |
Publication Type | Journal Article |
Year of Publication | 2012 |
Authors | Fountzilas, G., Christodoulou C., Bobos M., Kotoula V., Eleftheraki A. G., Xanthakis I., Batistatou A., Pentheroudakis G., Xiros N., Papaspirou I., Koumarianou A., Papakostas P., Bafaloukos D., Skarlos D. V., & Kalogeras K. T. |
Journal | J Transl Med |
Volume | 10 |
Pagination | 212 |
Date Published | 2012 Oct 23 |
ISSN | 1479-5876 |
Keywords | Antigens, Neoplasm, Breast Neoplasms, DNA Topoisomerases, Type II, DNA-Binding Proteins, Female, Genes, erbB-2, Humans, Immunohistochemistry, Neoplasm Metastasis, Paraffin Embedding, Poly-ADP-Ribose Binding Proteins, Prognosis |
Abstract | BACKGROUND: The vast majority of patients with HER2-positive metastatic breast cancer (MBC) treated with trastuzumab eventually develop resistance to this agent. There is an unmet need therefore, for identifying biological markers with possible prognostic/predictive value in such patients. The aim of this study was to investigate the prognostic role of topoisomerase II alpha gene (TOP2A) amplification and protein (TopoIIa) expression in patients treated with trastuzumab-containing regimens. |
DOI | 10.1186/1479-5876-10-212 |
Alternate Journal | J Transl Med |
PubMed ID | 23092535 |
PubMed Central ID | PMC3499161 |